Novogene Co., Ltd. provides genomic services and solutions worldwide. The company offers genomic solutions, such as human genome sequencing, gene regulation, single cell sequencing, animal and plant solutions, and microbial genome sequencing; and cancer genomic profiling, whole exome sequencing, and FFPE RNA sequencing, as well as clinical-grade whole exome sequencing services. It also provides NovoFocus, a next-generation sequencing based companion diagnostic assay for PARP inhibitor therapies; and NovoNeoantigen, a bioinformatics pipeline for the identification of cancer neoantigens with whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples. Novogene Co., Ltd. has a strategic partnership with Hummingbird Bioscience Pte. Ltd. to support the development of investigational drug candidate HMBD-001, an anti-HER3 antibody to be evaluated for treatment of various tumor types, including NRG1-fusion driven cancers. The company was founded in 2011 and is headquartered in Beijing, China.

Novogene Co., Ltd.

Novogene provides genomic services and solutions, leveraging next-generation sequencing (NGS) and bioinformatics expertise.

	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue					1.53B -	1.49B 2.92%			2.00B -
cost of revenue					933.89M -	966.68M 3.51%
gross profit					600.94M -	523.35M 12.91%			2.00B -
selling and marketing expenses					229.81M -	235.55M 2.50%
general and administrative expenses					35.86M -	24.61M 31.38%
selling general and administrative expenses					265.67M -	260.15M 2.08%
research and development expenses					125.71M -	112.31M 10.65%		125.57M -
other expenses	3.16M -	5.26M 66.46%	-22.17K 100.42%	-25.95K 17.07%	77.45M 298,540.15%	86.68M 11.92%	94.22M 8.70%	119.87M 27.23%	-1.79B 1,591.75%
cost and expenses	279.35M -	410.49M 46.95%			1.40B -	1.43B 1.65%			1.79B -
operating expenses	131.82M -	172.08M 30.55%	252.08M 46.49%	338.52M 34.29%	468.82M 38.49%	459.15M 2.06%	543.62M 18.40%	609.44M 12.11%	1.79B 193.42%
interest expense					2.68M -	10.27M 282.70%
ebitda					222.13M -	164.22M 26.07%			179.67M -
operating income					119.27M -	58.57M 50.90%			214.07M -
depreciation and amortization	11.61M -	21.31M 83.53%			102.86M -	105.65M 2.71%			-34.41M -
total other income expenses net									-2.25M -
income before tax					119.21M -	35.53M 70.19%			211.83M -
income tax expense					4.78M -	1.09M 77.21%			34.41M -
net income	24.79M -	39.13M 57.86%	80.50M 105.73%	97.10M 20.62%	114.29M 17.70%	36.54M 68.03%	224.99M 515.74%	177.23M 21.23%	177.42M 0.11%
weighted average shs out		115.09M -	365.92M 217.94%	359.62M 1.72%	400.20M 11.28%	400.20M 0%	388.27M 2.98%	402.80M 3.74%	403.23M 0.11%
weighted average shs out dil		115.09M -	365.92M 217.94%	359.62M 1.72%	400.20M 11.28%	400.20M 0%	388.27M 2.98%	402.80M 3.74%	403.23M 0.11%
eps	0 -	0.34 Infinity%	0.22 35.29%	0.27 22.73%	0.29 7.41%	0.09 68.52%	0.58 535.27%	0.44 24.14%	0.44 0%
epsdiluted	0 -	0.34 Infinity%	0.22 35.29%	0.27 22.73%	0.29 7.41%	0.09 68.52%	0.58 535.27%	0.44 24.14%	0.44 0%

6883

COM:NOVOGENE

Novogene

Last Close

13.56

22/11 07:00

Market Cap

4.43B

Beta: -

Volume Today

3.59M

Avg: -

Preview